Antibody levels after BNT162b2 vaccine booster and SARS-CoV-2 Omicron infection

Vietri, Maria Teresa; D’Elia, Giovanna; Caliendo, Gemma; Passariello, Luana; Albanese, Luisa; Molinari, Anna Maria; Angelillo, Italo Francesco

doi:10.1016/j.vaccine.2022.08.045

Cited by 15 publications

(13 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Booster vaccination restored the antibody concentrations, even higher than the concentrations after the first vaccination cycle. However, this increase was not significant, which differs from a few recent reports [15,16]. This discrepancy may be attributed to our reduced sample size, as reports from Salvagno and Teresa Vietri et al .…”

Section: Discussioncontrasting

confidence: 99%

The impact of BNT162b2 mRNA vaccine on adaptive and innate immune responses

Föhse

Geckin

Zoodsma

et al. 2021

Preprint

View full text Add to dashboard Cite

The mRNA-based BNT162b2 vaccine from Pfizer/BioNTech was the first registered COVID-19 vaccine and has been shown to be up to 95% effective in preventing SARS-CoV-2 infections. Little is known about the broad effects of the new class of mRNA vaccines, especially whether they have combined effects on innate and adaptive immune responses. Here we confirmed that BNT162b2 vaccination of healthy individuals induced effective humoral and cellular immunity against several SARS-CoV-2 variants. Interestingly, however, the BNT162b2 vaccine also modulated the production of inflammatory cytokines by innate immune cells upon stimulation with both specific (SARS-CoV-2) and non-specific (viral, fungal and bacterial) stimuli. The response of innate immune cells to TLR4 and TLR7/8 ligands was lower after BNT162b2 vaccination, while fungi-induced cytokine responses were stronger. In conclusion, the mRNA BNT162b2 vaccine induces complex functional reprogramming of innate immune responses, which should be considered in the development and use of this new class of vaccines.

show abstract

Section: Discussioncontrasting

confidence: 99%

The impact of BNT162b2 mRNA vaccine on adaptive and innate immune responses

Föhse

Geckin

Zoodsma

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…Numerous recent studies have described the increased infectivity of Omicron subvariants, suggesting three to ten times compared to Delta and its previous variants [ 11 , 12 ]. Additionally, Omicron subvariants have consistently demonstrated their ability to evade neutralizing antibodies in those who had received three prior mRNA vaccines, as well as those with antibodies acquired from natural infection preceding the initial Omicron wave [ 6 , 11 , [13] , [14] , [15] ]. Fortunately, lower respiratory involvement and severity of disease had decreased, resulting in fewer hospitalizations throughout the country [ 11 , 15 ].…”

Section: Discussionmentioning

confidence: 99%

“…Additionally, Omicron subvariants have consistently demonstrated their ability to evade neutralizing antibodies in those who had received three prior mRNA vaccines, as well as those with antibodies acquired from natural infection preceding the initial Omicron wave [ 6 , 11 , [13] , [14] , [15] ]. Fortunately, lower respiratory involvement and severity of disease had decreased, resulting in fewer hospitalizations throughout the country [ 11 , 15 ]. Towards the end of January 2022, our institution had over 500 hospital employees on home quarantine due to acute COVID-19 infection and our system had greater than a 99% full vaccination rate, yet our number of COVID-19 units decreased from six to two within two months.…”

Section: Discussionmentioning

confidence: 99%

“…Finally, all of our subjects had MFI levels RBD ≥ 700 regardless of reaction to the nucleocapsid. Prior studies have suggested that even following a booster, antibody levels may begin to wane as early as three and commonly by six months [ 15 , 18 , 19 ]. This is encouraging within our cohort of providers considering that the mean time since their last booster was seven months, which may have contributed to our lower-than-expected incidence of prior infection.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Incidence of unknown COVID-19 infection in a cohort of emergency physicians and advance practice providers

Barksdale¹,

Wood²,

Branecki³

et al. 2023

The American Journal of Emergency Medicine

View full text Add to dashboard Cite

“…Indeed, in people older than 60 years, a booster dose has been shown to confer greater protection against both infection and hospitalization compared to just two doses [ 5 ]. A booster dose of mRNA vaccines increases the levels of antibodies and protection against COVID-19 disease [ 6 ]. Yet, a matched, case-control study indicated that a booster dose is more protective against Delta variant than it is against Omicron [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

Effect of COVID-19 Vaccination on the In-Hospital Prognosis of Patients Admitted during Delta and Omicron Waves in Italy

et al. 2023

View full text Add to dashboard Cite

All-cause mortality related to the SARS-CoV-2 infection has declined from the first wave to subsequent waves, probably through vaccination programs and the availability of effective antiviral therapies. Our study aimed to evaluate the impact of the SARS-CoV-2 vaccination on the prognosis of infected patients. Overall, we enrolled 545 subjects during the Delta variant wave and 276 ones during the Omicron variant wave. Data were collected concerning vaccination status, clinical parameters, comorbidities, lung involvement, laboratory parameters, and pharmacological treatment. Outcomes were admission to the intensive care unit (ICU) and 30-day all-cause mortality. Overall, the final sample included 821 patients with a mean age of 62 ± 18 years [range 18–100], and 59% were men. Vaccinated patients during the Delta wave were 37% (over ¾ with two doses), while during the Omicron wave they were 57%. Vaccinated patients were older (68 vs. 57 years), and 62% had at least one comorbidity Admission to the ICU was 20%, and the mortality rate at 30 days was 14%. ICU admissions were significantly higher during the Delta wave than during Omicron (OR 1.9, 95% CI 1.2–3.1), while all-cause mortality did not differ. Unvaccinated patients had a higher risk of ICU admission (OR 2.0, 95% CI 1.3–3.1) and 30-day all-cause mortality (OR 1.7, 95% CI 1.3–2.7). Results were consistent for both Delta and Omicron variants. Overall, vaccination with at least two doses was associated with a reduced need for ICU admission. Even one shot of the vaccine was associated with a significantly reduced 30-day mortality.

show abstract

Antibody levels after BNT162b2 vaccine booster and SARS-CoV-2 Omicron infection

Cited by 15 publications

References 32 publications

The impact of BNT162b2 mRNA vaccine on adaptive and innate immune responses

The impact of BNT162b2 mRNA vaccine on adaptive and innate immune responses

Incidence of unknown COVID-19 infection in a cohort of emergency physicians and advance practice providers

Effect of COVID-19 Vaccination on the In-Hospital Prognosis of Patients Admitted during Delta and Omicron Waves in Italy

Contact Info

Product

Resources

About